Sudeep Pharma Limited announced a strong performance for the second quarter and first half of FY27. The company achieved a record quarterly revenue of INR196 crores, a 21% increase year-on-year, and a record EBITDA of INR73 crores, up 32%. This growth was driven by strong performance in its core businesses, improved margins, and contributions from Specialty Ingredients, Pharma Food Nutrition, and Battery Materials segments. The company also highlighted progress in its greenfield facility and battery materials project.
Sudeep Pharma Delivers Record Q2 FY27 Performance
Sudeep Pharma Limited has reported its financial results for the second quarter and first half of the financial year 2027, showcasing a period of significant growth and record-breaking performance. The company announced its Q2 FY27 revenue from operations stood at INR196.7 crores, marking a 21% year-on-year increase from INR162.7 crores in Q2 FY26. Sequentially, revenue grew by 24% from INR158.3 crores in Q1 FY27. The company achieved its highest-ever quarterly EBITDA at INR73.2 crores, a 32% increase compared to INR55.5 crores in Q2 FY26 and a 33% sequential growth from INR54.9 crores in Q1 FY27. The EBITDA margin improved to 37.2%.
Key Segmental Updates
The Pharma Food Nutrition (PFN) segment continued to show robust growth, with revenue increasing by 57% year-on-year to INR142 crores, contributing approximately 72% of the consolidated revenue. The segment EBITDA margin improved significantly to approximately 41%. The Specialty Ingredients segment saw revenue of INR54 crores, up 9% sequentially, though down 25% year-on-year, impacted by the pause in the Fortified Rice program. However, new customer approvals are expected to drive sequential growth in Q3 and Q4. The Battery Materials business is progressing with the Dahej project, aiming for commercial operations in April 2027 with an initial capacity of 25,000 tons of battery-grade iron phosphate.
Financial Highlights and Outlook
Profit after tax for Q2 FY27 was INR51.8 crores, an 11% increase year-on-year. For the first half of FY27, revenue grew 23% year-on-year to INR355 crores, with EBITDA growing 29% to INR128.1 crores. The company maintained a conservative balance sheet, with net debt at INR72.5 crores as of September 30, 2026. Sudeep Pharma expressed confidence in its business plans, focusing on high-value products, pricing discipline, and operational efficiency to achieve its growth objectives for FY27. The company is also expanding its product portfolio, including new glycinate, gluconate, and citrate products, and is seeing growing interest in its battery materials business.
Source: BSE
